Nine new Challenge Programme grants from the Novo Nordisk Foundation will support ambitious research across fungal diseases, cardiometabolic disease, soil health and non-equilibrium biological systems. With a European expansion, the 2026 awards unite strong research groups and diverse expertise across Europe in the pursuit of novel knowledge addressing major scientific challenges. Read more…
Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – June 2026 on 22 July, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam Cutler, CFO, […]
Neuried/Nesle, 8 July 2026 – AMSilk, a global leader in biotech produced silk materials, today announced a significant expansion of its partnership with Ajinomoto Foods Europe (AFE), marking a key step in scaling the industrial production of its silk proteins. Building on the collaboration first established in 2023, the two companies have now entered into […]
Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data Introduces a first-of-its-kind living vascular access solution for patients requiring hemodialysis EINDHOVEN, The Netherlands – 7 July, 2026 – Xeltis, a leading developer of transformative implants […]
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic […]
